Seeking Alpha

More on Merck (MRK) Q3 earnings: FY2012 guidance narrowed to EPS of $3.78-$3.82 from...

More on Merck (MRK) Q3 earnings: FY2012 guidance narrowed to EPS of $3.78-$3.82 from $3.75-$3.85. Forgetting currency issues, revenue is expected at or near 2011 level. Singulair sales -55% Y/Y. Patent expires in Europe in Feb. and company expects declining sales there similar to what happened in the U.S. Januvia/Janumet sales +15%, Zetia/Vytorin sales -1%. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)